these findings suggest that EndoCD/5-FC could become an alternative option for future antiangiogenesis therapy.
Introduction
Several anticancer drugs that target angiogenesis by blocking vascular endothelial growth factor/receptor (VEGF/VEGFR) have shown promise and have been approved by the FDA for clinical treatment of various cancer types (1) . These drugs include bevacizumab (Avastin), a humanized VEGF-neutralizing monoclonal VEFG antibody, and sorafenib and sunitinib, small molecular inhibitors that block VEGF receptor tyrosine kinase activity. Although these agents have successfully inhibited primary tumor growth and progression, there is no curative potential activity (2, 3) . In addition to causing severe adverse effects such as cardiotoxicity, gastrointestinal perforation, poor wound healing, and hypertension, induced by antiangiogenic treatment (4, 5) , recent reports also indicated that anti-VEGF therapy enhances tumor progression by increasing invasion and metastasis (6, 7) .
Tumors require the VEGF pathway for progression; however, stimulation of other angiogenesis factors may occur after VEGF/VEGFR targeted therapy and induce tumor resistance to antiangiogenesis monotherapy (8) . For example, in addition to VEGFstimulated angiogenesis, six other proangiogenic growth factors contribute to various stages of breast cancer progression (9) ; in addition, several intracellular molecules have been identified that modulate tumor angiogenesis (10) . Since it is not sufficient to inhibit tumor growth with use of antiangiogenesis monotherapy, a combination approach with chemotherapy is commonly used to improve the clinical benefits of antiangiogenic drug treatment (11) . Although combination therapy may reduce tumor resistance and enhance therapeutic efficiency compared with use of a single antiangiogenic drug, increased toxicity results in shorter progression-free survival (12) . Initially, anti-VEGF/VEGFR antiangiogenic drugs were not expected to cause toxic effects or drug resistance; however, increasing numbers of clinical reports have demonstrated that inhibition of the VEGF signaling pathway has led to off-target effects that influenced normal body homeostasis (13) . Some adverse effects include potentially life-threatening complications such as gastrointestinal perforation with short-term treatment and a reduced left ventricular ejection fraction (LVEF) in the heart with long-term treatment.
Drugs that block angiogenesis can be classified as either direct or indirect inhibitors (2) . Compared with direct angiogenic inhibitors, indirect anti-VEGF/VEGFR agents are more likely to induce drug resistance because they target genetically altered and unstable tumor cells rather than genetically stable endothelial cells (2, 14) . Endostatin (Endo), an angiogenesis inhibitor that targets unique proliferating endothelial cells and inhibits proliferation, migration, and invasion (15) through interaction with the α v β 3 and α 5 β 1 integrin receptors (16) , was tested in multiple clinical trials (17, 18) without causing severe adverse effects or drug resistance. However, due to poor clinical response and its short protein half-life, Endo was not further pursued in clinical trials after phase II studies in the United States (19, 20) .
Cytosine deaminase is an enzyme capable of converting 5-fluorocytosine (5-FC) prodrug into cytotoxic 5-fluorouracil (5-FU) (21) . A fusion gene consisting of cytosine deaminase and uracil phosphoribosyl transferase (for simplicity, we will refer to this fusion gene as CD throughout this article) was reported to increase the 5-FC/5-FU conversion rate to 10,000 times the rate observed with use of a single enzyme alone (22) and is well known to produce bystander effect in cancer cell killing in a gene therapy setting (23, 24) . However, since it is difficult to target chemotherapy specifically to the tumor site, systemic treatment will have off-target issues and cause unwanted adverse effects.
In this study, we report an engineered endostatin-CD (EndoCD) (25) fusion protein that provides a wider therapeutic window, higher therapeutic efficacy and safety, and lower drug resistance potential for cancer treatment. We compared the therapeutic efficacy of EndoCD plus 5-FC (EndoCD/5-FC) and bevacizumab plus 5-FU (bevacizumab/5-FU) and found that EndoCD/5-FC surpassed bevacizumab/5-FU in several aspects: 1) EndoCD/5-FC exhibited potent antitumor activity by increasing 5-FU concentration locally at the tumor site, resulting in higher therapeutic efficacy; 2) EndoCD/5-FC decreased metastasis; 3) EndoCD/5-FC did not induce cardiotoxicity or cardiac function failure as monitored by magnetic resonance imaging (MRI) over a prolonged period. Our findings demonstrate that EndoCD fusion protein is an excellent candidate as an antiangiogenic inhibitor to be tested in future clinical trials.
Materials and Methods
Detailed methodology is described in the Supplementary Methods. 
Results
Previously, we developed a gene therapy-based EndoCD treatment that was both antiangiogenic and cytotoxic and had significant antitumor effect in vivo (25) .
However, since the FDA has not approved a single human gene therapy as a drug to date, a protein-based therapy of EndoCD would be more practical for obtaining FDA approval. To achieve this goal, we constructed a recombinant protein expression vector containing the human Endo and yeast CD fusion gene that was engineered to express EndoCD as a single polypeptide (Fig. 1a) . As an endothelial cell-targeting agent, Endo would bring CD to the tumor site as Endo targets tumor vasculature (27) , and once at the tumor site, CD could then convert 5-FC to cytotoxic 5-FU and induce apoptosis. Due to the differences in the molecular weight of Endo, CD, and EndoCD (20 kDa, 40 kDa, and 60 kDa, respectively), we used a ratio of 1:2:3 of the proteins for all the experiments in this study to ensure equal molarity (Fig. 1b) .
To determine the stability of the purified protein in serum, 12.5 μM of each purified, his-tagged protein (Endo, CD, and EndoCD) was mixed immediately with mice serum, incubated at 37°C for the number of days indicated, and analyzed by immunoblotting with use of anti-his-tag antibody ( Supplementary Fig. 1a ). We found that although Endo had a short protein half-life of less than one day, which is consistent with previous clinical reports (28), EndoCD fusion protein had much longer protein stability and creatinine. Clearly, AST, ALT, BUN, and creatinine levels in EndoCD-treated mice were all within the normal range (30) (Supplementary Fig. 3 ). In addition, no mice in the EndoCD/5-FC treatment group displayed any obvious symptoms such as loss of appetite or inactivity or died more than 2 months after initial treatment, when the experiment was terminated (data not shown). Thus, these results suggest that treatment with EndoCD/5-FC produced virtually no toxicity or nondetectable toxicity in mice. We observed significantly better tumor suppression in mice treated with EndoCD/5-FC than in those treated with bevacizumab or 5-FU alone (Fig. 3a, 3b ).
Although we did not observe a significant difference in tumor reduction between EndoCD/5-FC and bevacizumab/5-FU under this condition, EndoCD/5-FC-treated mice had a better overall mean survival rate than did those treated with bevacizumab/5-FU (p = 0.004) in the 620-L-1 model (Fig. 3c) . To further investigate whether the treatment schedule might affect antitumor activity, we decreased the number of drug treatments to only 5 and showed that EndoCD/5-FC had much better antitumor activity and metastasis suppression activity than did bevacizumab/5-FU in the metastatic colon cancer model on day 35 after tumor inoculation (Fig. 3d) . Similar results were obtained in the MDA-MB-231 orthotopic tumor mouse model, although the efficiency in the breast cancer model (Fig. 3e) was not as dramatic as that in the colon cancer model (Fig. 3d) . These results suggested that EndoCD/5-FC treatment resulted in stronger antitumor activity than did bevacizumab/5-FU treatment.
As mentioned above, VEGF/R inhibitors reduce primary tumor growth; however, due to the cytostatic nature of these drugs, tumor cells that might have survived could become more malignant, as suggested in recent studies that presented evidence that these drugs may increase tumor invasiveness and metastasis (32) . To address whether EndoCD/5-FC treatment also promotes tumor invasiveness and metastasis, we used the stable 620-L-1 cell line expressing luciferase to facilitate detection of colon to liver metastasis in real time by IVIS imaging. After 35 days of tumor cell inoculation, we found that mice that were treated with EndoCD did not have increased liver metastasis compared with those that received bevacizumab/5-FU (Fig. 3f patients (33) . To examine the contribution of these drug treatments to cardiotoxicity, we collected serum from mice (Fig. 3b ) treated with 15 mg/kg of 5-FU, 60 mg/kg of EndoCD plus 500 mg/kg of 5-FC, 10 mg/kg of bevacizumab, or 10 mg/kg of bevacizumab plus 15 mg/kg of 5-FU and compared levels of troponin I, a marker of cardiomyocyte damage, from these groups with levels from the untreated control group. We found that bevacizumab-and bevacizumab/5-FU-treated mice had a substantially higher troponin I serum concentration than the other groups did, which showed essentially no troponin I ( Supplementary Fig. 4 ).
To further investigate the impact of EndoCD/5-FC and bevacizumab/5-FU on the heart, we determined the occurrence of cardiac fibrosis by measuring hydroxyproline for collagen accumulation and using trichrome staining to directly evaluate the amount of collagen in the heart tissue. Mice were treated with 60 mg/kg of EndoCD plus 500 mg/kg of 5-FC (twice per week) and 10 mg/kg of bevacizumab (once every 2 weeks) plus 15 mg/kg of 5-FU (once per week); after 6 months of treatment, the hearts were harvested from mice for proline hydroxylation measurement. Mice that were given bevacizumab/5-FU had higher levels of proline hydroxylation (Fig. 4a) and increased cardiac fibrosis (blue color indicated by arrows; Fig. 4b ) than did mice of the same age in the control and EndoCD/5-FC treatment groups. Previously, it was shown that VEGF plays an important role in myocardial angiogenesis and that the loss of VEGF-impaired cardiac function leads to ischemic cardiomyopathy in mice (34) . As serum VEGF concentration significantly decreased under anti-VEGF treatment (Fig. 4c) , a concurrent reduction in vascular density of heart tissue was observed, indicated by the loss of CD31 signal under anti-VEGF treatment (Fig. 4d) , which is consistent with the expected evidence that EndoCD/5-FC not only targets tumor angiogenesis specifically but also reduces surviving tumor cells, thus decreasing the incidence of tumor invasiveness and metastasis. Taken together, the dual-targeting antiangiogenic and chemotherapeutic strategy we have developed may provide a new therapy to prevent tumor recurrence, decrease tumor metastasis, and eliminate unwanted cytotoxic adverse effects.
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